
Mesoblast fell 21.8% from $14.89 to $11.64, behind the S&P 500's +10.6%. Its worst day was Jan 12 (−10.9%), and its low came Nov 18 at $11.64.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Mesoblast closed at its highest level of the year, 40.8% above where the year started.
+5.5% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
EPS of $-0.03 beat the $-0.20 estimate on $51.3M revenue (est. $17.6M).
−6.3% · S&P 500 −0.5%
Mesoblast shares rose 9.3%, while the S&P 500 rose 0.6%.
+9.3% · S&P 500 +0.6%
Mesoblast shares rose 9.1%, while the S&P 500 fell 0.5%.
+9.1% · S&P 500 −0.5%
EPS of $-0.04 beat the $-0.50 estimate on $120.3M revenue (est. $180.9M).
+8.0% · S&P 500 +0.7%
Mesoblast shares fell 10.0%, while the S&P 500 rose 0.4%.
−10.0% · S&P 500 +0.4%
Mesoblast shares rose 17.0%, while the S&P 500 fell 0.4%.
+17.0%, the year's best day · S&P 500 −0.4%
Where it ended: a close of $11.64 on Nov 18, 2026. Up next: H1 2027 earnings on Feb 25, 2027 (revenue est. $52.3M).
Nothing in the past 12 months.
All MESO dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MESO and SPY from Benzinga historical bars. Not investment advice.